Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor
Sponsor: University Hospital, Clermont-Ferrand
Summary
Essential head tremor (HT) does not usually respond to drug treatment such as propranolol or primidone or to surgical treatment such as deep brain stimulation of the thalamic ventralis intermedius nucleus. Botulinum toxin (Btx) is widely used and efficient in the treatment of blepharospasm and cervical dystonia. Btx prevents the release of acetylcholine in synapses, leading to a reduction of pathological muscle movement. Very little information is available on its efficacy on HT. Two published reports suggested that local Btx A injections could be an effective and safe approach for treating HT. Given the scarcity of published data (small samples, open studies, different doses of Btx used, heterogeneous populations, several muscles injected, etc.), the aim of this study is to demonstrate the efficacy of Btx injections in essential HT by a multi-center, randomized, double-blind, parallel-group, placebo-controlled study. Principal objective: To evaluate the efficacy of botulinum toxin injections in the treatment of head tremor. Secondary objectives: * \- To evaluate the tolerance of botulinum toxin injections in the treatment of head tremor. * \- To evaluate the impact of botulinum toxin injections on the patients' quality of life and embarrassment. * To evaluate the changes of tremor characteristics induced by a Btx treatment using a 3D accelerometer wireless portable system (Xsens MTw wireless motion tracker system) (tremor frequency, tremor displacement, mean peak amplitude, distance traveled) and a new video system device to analyze head tremor characteristics
Official title: Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2016-06-27
Completion Date
2022-09-01
Last Updated
2026-04-21
Healthy Volunteers
No
Conditions
Interventions
BOTOX ® 200 Unités
Patients eligible for inclusion will be randomized to one of the two groups: * Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis). * Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Placebo
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Locations (17)
Centre Hospitalier Pays D'Aix
Aix-en-Provence, France
CHU d'Amiens
Amiens, France
Hôpital Jean Minjoz
Besançon, France
Hôpital Haut-Levêque
Bordeaux, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Hôpital R Salendro
Lille, France
Hôpital neurologique
Lyon, France
Hôpital de la Timone
Marseille, France
CH Narbonne
Narbonne, France
Hôpital Caremeau
Nîmes, France
AP-HP
Paris, France
Fondation Rothschild
Paris, France
Hopital Lariboisière
Paris, France
Hôptal Avicenne de Bobigny
Paris, France
CHU de Poitiers
Poitiers, France
Hôpital de Hautepierre
Strasbourg, France
CHU de Toulouse
Toulouse, France